Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br Rationale and Conventional Use of Alkylating Agents and P
2021-03-09

Rationale and Conventional Use of Alkylating Agents and Platinum Derivatives in Clinical Practice After the attack on Bari Harbor in 1943 revealed the effects of mustard gas on bone marrow depletion and the first therapeutic outcomes in lymphoma, alkylating agents gradually became a gold standard
-
br Conclusion New series of thiazolo d pyridazine
2021-03-09

Conclusion New series of thiazolo[4,5-d]pyridazine and imidazo[2′,1′:2,3]thiazolo[4,5-d]pyridazine were designed and synthesized using thiazole as scaffold based on its previously observed activity as DHFR inhibitor. Compounds 13 and 43 (Fig. 9) proved to be the most active DHFR inhibitors with I
-
Table shows the clinical data of recipients
2021-03-09

Table 2 shows the clinical data of 23 recipients with CYP3A5*1 allele classified by the presence or absence of CYP3A phenoconversion. Phenoconversion of CYP3A was observed in 10 recipients with CYP3A5*1 allele. No significant differences in eGFR, ALT and total bilirubin were observed between recipie
-
fgfr1 br Conflict of interest br Acknowledgments Dr Hauger
2021-03-09

Conflict of interest Acknowledgments Dr. Hauger was supported by a BLR&D Merit Review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. Dr. Hauger also received support from the VA Center of Excellence for Stress and Mental Healt
-
Employing distinct genetic and pharmacological approaches Di
2021-03-09

Employing distinct genetic and pharmacological approaches, Divakaruni et al. now demonstrate that macrophages still acquire their IL-4-elicited phenotype in the absence of CPT1a (considered the main isoform in leukocytes) or CPT2, and highlight that the increased LC-FAO in M(IL-4) cells is less cruc
-
Mass spectrometry has previously been used to
2021-03-09

Mass spectrometry has previously been used to examine the presence of Hyp in recombinant collagen, using hydrolysates to identify the individual imino acid, equivalent to an amino Hydroxyfasudil analysis [33], and also by analysis of mass changes to tryptic peptides [34]. The present study, however,
-
NB-598 Maleate br Allosteric inhibitors In general
2021-03-09

Allosteric inhibitors In general, candidate drugs that bind to a GPCR at a site that is distinct (allosteric site) from the binding site of the endogenous agonist (orthosteric site) are attracting increasing attention 39, 42, 58. Allosteric modulators display saturability of their effect, probe d
-
Our earlier experimental studies showed neutral i e non
2021-03-09

Our earlier experimental studies showed "neutral", i.e. non-proliferative, effects of progesterone but a large increase in proliferation using certain progestins; however, this was only in the presence of PGRMC1 [[13], [14], [15], [16], [17], [18], [19]]. The next step was to investigate whether thi
-
In rodent models the loss of estrogens
2021-03-09

In rodent models, the loss of estrogens through ovariectomy has been shown to promote the development of intracranial aneurysms. Conversely, the administration of an Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) receptor beta agonist restores its protective effect, but is abolished with the
-
Several questions remain to be
2021-03-09

Several questions remain to be addressed. The hormones and metabolites that modulate expression of EERγ in the steps leading to maturation need to be identified to learn more about physiological and pathophysiological regulation of EERγ in β cells. Considering that ERRγ repressed cell cycle genes in
-
capmatinib br Conflict of interest br Acknowledgements This
2021-03-09

Conflict of interest Acknowledgements This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2013R1A1A1076117) and also by the Priority Research Centers Program through the NRF funde
-
In conclusion we provide convincing evidence that the
2021-03-09

In conclusion, we provide convincing evidence that the PRRSV-induced SGs are indeed bona fide SGs. While we determined that mRNA is present in the PRRSV-induced SGs, we did not distinguish its origin. Future studies will need to determine whether the mRNA stored in PRRSV-induced SGs is of cellular o
-
br Oxysterols as Key Players
2021-03-09

Oxysterols as Key Players in Metabolic Syndrome? Obesity and sedentary lifestyle are on the rise and pose serious threats to people's health and wellbeing. Obesity is often associated with other pathologies and is one of the criteria included in the definition of metabolic syndrome (MetS) (see Gl
-
The HEV vaccine developed based on p particles is
2021-03-09

The HEV vaccine, developed based on p239 particles, is of good efficacy, immunogenicity and safety, and was licensed in China in 2012. p239 (aa 368–606) and E2 (aa 394–606) share a common region of ORF2, referred to as E2s (aa 459–606), which harbors the major antigenic determinants of the HEV vacc
-
C PHNO has been described as
2021-03-08

[11C]-(+)-PHNO has been described as a full agonist at both D2 and D3 receptors [54,55]. [11C]-(+)-PHNO was initially developed as a PET radiotracer for imaging the high affinity state of the D2 receptor (i.e., highD2) as a means of measuring synaptic dopamine changes in response to pharmacologic ch
14951 records 682/997 page Previous Next First page 上5页 681682683684685 下5页 Last page